

Tchaikapharma High Quality Medicines Inc.
Statement of financial position
as of 31 December 2021

	31.12.2021	31.12.2020
	BGN'000	BGN'000
ASSETS		
Non-current assets		
Property, plant and equipment	38 071	37 333
Intangible assets	3 451	3 816
Investments in subsidiaries	19	19
Trade receivables	5 276	5 157
Total non-current assets	46 817	46 325
Current assets		
Inventories	11 342	10 842
Trade and other receivables	59 220	60 084
Current corporation tax	40	14
Treasury shares redeemed	-	1
Cash and cash equivalents	40	45
Total current assets	70 642	70 986
Total assets	117 459	117 311
LIABILITIES		
Equity		
Share capital	84 500	82 200
Reserves	12 382	12 032
Retained earnings	1 940	2 904
Total	98 822	97 136
Non-current liabilities		
Long-term loans	1 717	1 731
Deferred tax liabilities	1 030	1 139
Retirement benefit obligations	151	194
Total non-current liabilities	2 898	3 064
Current liabilities		
Trade and other liabilities	4 720	6 583
Short-term loans	9 781	9 783
Current portion of long-term loans	990	541
Current corporate income tax	125	
Other tax liabilities	123	204
Total current liabilities	15 739	17 111
Total liabilities	18 637	20 175
Total equity and liabilities	117 459	117 311

Date of preparation: 25.03.2022

Sofia Prepared by:.....
 / P. Moneva /

Executive Director.....
 /B. Georgiev/

Date of certification: 29.03.2022

Auditor:
 Asen Kitov



Tchaikapharma High Quality Medicines Inc.
Statement of comprehensive income
for the year ended 31 December 2021

	31.12.2021	31.12.2020
	BGN'000	BGN'000
Revenue	42 431	40 105
Other income	124	283
Total income	42 555	40 388
Carrying amount of goods sold	(1 105)	(817)
Changes in inventories of finished products and work in progress	1 020	(784)
Materials and services	(30 678)	(28 405)
Personnel expenses	(5 680)	(4 960)
Depreciation / amortisation expenses	(3 877)	(4 231)
Depreciation costs		(50)
Other expenses	(776)	(602)
Finance income	507	521
Finance costs	(399)	(436)
Total expenses	(40 988)	(39 764)
Profit before taxation	1 567	624
Corporate income tax expense	(168)	(20)
Profit/Loss for the period	1 399	604
Gain/(Loss) on revaluation of the fair value of land and buildings	246	
Changes due to deferred tax for land and buildings	(31)	(7)
Revaluation of defined benefit pension funds	80	(4)
Changes due to deferred tax for pension funds	(8)	
Other comprehensive income for the period		
Total comprehensive income for the period	1 686	593
Earnings per share / in BGN per 1 share /	0.02	0.007

Date of preparation: 25.03.2022

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Date of certification: 29.03.2022

Auditor:

Asen Kitov



Tchaikapharma High Quality Medicines Inc.
Cash flow statement
for the year ended 31 December 2021

	31.12.2021	31.12.2020
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	33 931	35 208
Payments to suppliers of materials, goods and services	(22 964)	(22 940)
Payments to personnel	(5 518)	(4 802)
Payments of interest and dividends	(30)	(19)
Corporate income tax payments	(218)	(352)
Other proceeds / payments	(3 176)	(3 609)
Net cash flows	2 025	3 486
Cash flows from investing activities		
Payments on non-current assets acquired	(1 573)	(2 907)
Other investing activities		(19)
Net cash flows	(1 573)	(2 926)
Cash flows from financial activities		
Proceeds from loans	199	200
Payments on loans	(201)	(201)
Payment of interest, dividends	(200)	(196)
Payments on finance lease	(459)	(358)
Other proceeds/payments	204	
Net cash flows	(457)	(555)
Change in cash and cash equivalents	(5)	5
Cash and cash equivalents at the beginning of the period	45	40
Cash and cash equivalents at the end of the period	40	45

Date of preparation: 25.03.2022

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director

.....
/B. Georgiev /

Date of certification: 29.03.2022

Auditor:

Asen Kitov



Tchaikapharma High Quality Medicines Inc.
Statement on changes in equity
for the year ended 31 December 2021

	Registered (share) capital	Revaluati on reserves	Other reserves	Retained earnings / loss	Total equity
	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'00</i> <i>0</i>	<i>BGN'000</i>
Balance as of 01.01.2020	82 200	4 099	7 676	2 568	96 543
Profit/loss for the period				604	604
Other comprehensive income		(11)			(11)
Including from tax effect of the revaluation of property, plant and equipment		(7)			
Total comprehensive income		(11)		604	593
Issue of shares by the owners					
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			268	(268)	
Total amount of income and expenses recognised during the period			268	(268)	
Balance as of 31.12.2020	82 200	4 088	7 944	2 904	97 136
Balance as of 01.01.2021	82 200	4 088	7 944	2 904	97 136
Profit/loss for the period				1 399	1 399
Other comprehensive income		287			287
Including tax effect from revaluation		(39)			(39)
Total comprehensive income		287		1 399	1 686
Issue of shares by the owners					
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves	2 300		63	(2 363)	
Total amount of income and expenses recognised during the period	2 300		63	(2 363)	
Balance as of 31.12.2021	84 500	4 375	8 007	1 940	98 822

Date of preparation: 25.03.2022

Prepared by:
/P. Moneva/

Executive Director
/B. Georgiev

Sofia

Date of certification: 29.03.2022

Auditor: Asen Kitov

